Topic Info
With the number of people age 65 and older expected to rise to 72 million by 2030, the effects of Alzheimer’s could have a devastating impact on this population of seniors. Intellect Neurosciences has invented ANTISENILIN® monoclonal antibodies for the treatment and prevention of Alzheimer’s disease. They have gained attention from several major pharmaceutical companies including Pfizer, Glaxo and Johnson and Johnson who have licensed the invention. Johnson and Johnson has invested $500 million into fast tracking the development of a cure.
Intellect Neurosciences founder, Dr Daniel Chain joins the show to discuss this potential cure for Alzheimer's disease.
Guest Info
Dr. Daniel G. Chain - Chief Executive Officer and Chairman of the Board Intellect Neurosciences -
Dr. Chain formed Intellect in April 2005 and has served as our Chief Executive Officer since October 2005. In July 1999, Dr. Chain founded Mindset Biopharmaceuticals USA, Inc., a biopharmaceutical development stage company, and Mindset Ltd., an Israeli research and development subsidiary of Mindset Biopharmaceuticals USA. In 2001, Dr. Chain founded MindGenix Inc., a contract drug testing company, as a subsidiary of Mindset Biopharmaceuticals USA. He served as Chief Executive Officer of Mindset Biopharmaceuticals USA from July 1999 until October 2005, when he resigned as the Chief Executive Officer of Mindset Biopharmaceuticals USA and joined Intellect. Dr. Chain continues to serve Mindset BioPharmaceuticals USA and MindGenix as president of both companies.
